Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) will likely be announcing its earnings results before the market opens on ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a biopharmaceutical company with a market capitalization of approximately $450 million, has been making significant strides in the market with its recently ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a biopharmaceutical company with a market capitalization of approximately $450 million, has been making significant strides in the market with its recently ...

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in ...

IntraBio's Aqneursa (levacetylleucine) has joined Zevra Therapeutics' Miplyffa (arimoclomol) for patients with Niemann-Pick type C (NPC), a rare genetic disease affecting around one in 100,000 ...